Methods and compositions for treating complement-associated disorders
The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders. In some embodiments, the inhibitor is chronically administered to patients. In some embodiments, the inhibitor is administered to a patient in an amount and with a frequency to maintain systemic complement inhibition and prevent breakthrough. In some embodiments, the compositions contain an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein or a fragment of the protein such as C5a or C5b.
1. A method for treating myasthenia gravis (MG) in an anti-AChR antibody positive patient, the method comprising administering eculizumab to a patient in need thereof in an amount effective to treat MG in the patient; wherein the administration schedule of eculizumab comprises: administering at least 600 mg of eculizumab once per week for the first four weeks of treatment; and, beginning one week after the initial four-week treatment, administering a maintenance dose of at least 900 mg of eculizumab every two weeks.
2. The method of claim 1 , wherein the patient exhibits a substantial improvement in at least two symptoms of MG during the first four weeks of treatment.
3. The method of claim 1 , wherein the maintenance dose of eculizumab is administered every two weeks until the patient's MG is in remission.